“We are getting too happy, for too little”: these words of a senior pharma journalist a decade back sound prophetic now. Consolidation, CRAMS, para IV filings and challenges to innovators, acquisitions, out-licensing, US and developed markets business growth – key themes a decade back – are now replaced with headwinds in US, pricing pressure in…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
